Compare Cassava Sciences Inc (FLNA) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs uniQure N.V. Ordinary Shares — how do they compare? Cassava Sciences Inc trades at $0.71 (market cap $35.91M), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: uniQure N.V. Ordinary Shares is far larger — about 41.2× Cassava Sciences Inc's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 38 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| FLNA | QURE | |
|---|---|---|
Market Cap | $35.91M | $1.48B |
Volume | 323,246 | 2,488,780 |
Sector | Health | Health |
52-Week High | $4.64 | $70.59 |
52-Week Low | $0.68 | $9.03 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | -$46.77M | $728.62M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.7434, down 3.39% today, with a bearish technical signal despite oscillator bullishness. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent FDA approval to lift the clinical hold on simufilam for TSC-related epilepsy is a positive development, with Phase 2a trials expected in early 2027.
Outlook remains speculative given negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include ongoing operational losses and dependence on clinical trial success. The stock presents high-risk biotech opportunity with potential upside from successful drug development.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
